The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1308 articles
Novo Nordisk has officially launched Wegovy®️ (semaglutide 2.4 mg) in Jordan, marking a significant advancement in the country's approach to tackling the growing challenge of excess weight and its associated health risks.
For years, Medicare's stance on GLP-1 medications for weight loss was a firm 'no.' However, a significant shift is underway. Discover how the new 'Bridge' program opens doors to crucial weight management tools like Wegovy and Mounjaro, and what you need to know.
Northern Ireland is set to launch a £5 million Regional Obesity Management Service, improving access to Mounjaro and lifestyle support for adults struggling with obesity.
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
While GLP-1 agonists have revolutionized weight loss for many, a significant portion of individuals don't experience the same dramatic results. This article delves into the reasons behind GLP-1 non-response and offers guidance for those seeking effective weight management solutions.
The landscape of weight loss and diet trends is undergoing a seismic shift, largely driven by the widespread adoption of GLP-1 receptor agonists. From Ozempic to Wegovy and Mounjaro, these medications are not just changing how individuals manage their weight but are fundamentally altering the food industry and the very concept of dieting.
A viral trend promoting a 'natural Ozempic' drink made with gelatin and water is sweeping social media. But does it live up to the hype? We explore the science behind this appetite suppressant and what health experts say about its effectiveness and safety.
The landscape of GLP-1 medications for weight loss and chronic disease management is rapidly evolving. From new access programs to shifting pricing dynamics, understanding these advancements is crucial for patients and healthcare providers alike.
As semaglutide medications become ubiquitous, we must balance their life-saving cardiovascular benefits with the dangers of normalizing extreme thinness and disordered eating behaviors.
